NCT01155947已完成1 期
An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fasting Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 主要终点
- Bioavailability based on Cmax and AUC parameters
研究概览
简要总结
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.
详细描述
Open label, balanced, randomized, two treatment, two-sequence, two periods, crossover, single dose, comparative oral bioavailability study in healthy, post menopausal women subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 37 Years 至 67 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •The subjects should be postmenopausal healthy women who have attained complete menopause naturally or surgically and have not had menstruation for at least one year and are not on hormone replacement therapy.
- •The subjects should have Estradiol level ≤ 20 pg/ml & serum follicular stimulating hormone (FSH) level ≥ 50 mlU/ml during the screening.
- •The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
- •The subjects should have a BMI between 18.5 to 26.4 (30-39 years), 18.5 to 27.8 (40-49 years), 18.5 to 28.4 (50-59 years) & 18.5 to 27.5 (60-69 years) weight in kg/ height2 in meter.
- •The subjects should be able to communicate effectively with study personnel.
- •The subjects should be able to give written informed consent to participate in the study.
排除标准
- •The subjects who have a history of allergic responses to Anastrozole or other related drugs.
- •The subjects who are using female hormone replacement therapies, thyroid hormone replacement therapies, or antihypertensive therapies.
- •The subjects who have significant diseases or clinically significant abnormal findings during screening, (medical history, physical examination, laboratory evaluations, ECG, X-ray & lower abdominal ultrasonography recordings).
- •The subjects who have any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •The subjects who have a history or presence of bronchial asthma.
- •The subject who have used of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
- •The subjects who have history of drug dependence, recent history of alcoholism or of moderate alcohol use.
- •The subjects who are smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who cannot refrain from smoking during study period.
- •The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
- •The subjects who have donated (1 unit: 350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
- •The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
- •The subjects who have a positive test result for Human Immunodeficiency Virus (HIV) antibody and / or syphilis Rapid Plasma Reagin, Venereal Disease Research Laboratory (RPR/VDRL).
- •The subject who received an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.
研究组 & 干预措施
Arimidex
Active Comparator
Arimidex® Tablets 1 mg
干预措施: Anastrozole (Drug)
Anastrozole
Experimental
Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
干预措施: Anastrozole (Drug)
结局指标
主要结局
Bioavailability based on Cmax and AUC parameters
时间窗: 3 Months
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed ConditionsHealthyNCT01155960Dr. Reddy's Laboratories Limited36
已完成
1 期
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting ConditionsHealthyNCT01375452Dr. Reddy's Laboratories Limited36
已完成
1 期
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed ConditionsHealthyNCT01372982Dr. Reddy's Laboratories Limited36
已完成
1 期
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleHealthy SubjectsNCT05551897AstraZeneca14
已完成
1 期
Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without WaterHealthy ParticipantsNCT01220167Aquestive Therapeutics18